Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
Richardson
Paul
P
Harvard Medical School Boston, Massachusetts, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019046:Bone Marrow Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016026:Bone Marrow Transplantation; D001897:Boronic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D000069286:Bortezomib; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000601:surgery; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000517:prevention & control; D011719:Pyrazines / Q000009:adverse effects / Q000627:therapeutic use*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib